Ignite Creation Date:
2024-05-06 @ 11:17 AM
Last Modification Date:
2024-10-26 @ 12:43 PM
Study NCT ID:
NCT03486912
Status:
COMPLETED
Last Update Posted:
2022-10-13
First Post:
2018-03-30
Brief Title:
A Study of Experimental Medication BMS-986036 in Adults With Nonalcoholic Steatohepatitis NASH and Liver Cirrhosis
Sponsor:
Bristol-Myers Squibb
Organization:
Bristol-Myers Squibb
Study Overview
Official Title:
A Phase 2B Randomized Double-Blind Placebo-Controlled Study Evaluating the Safety and Efficacy of BMS-986036 PEG-FGF21 in Adults With Nonalcoholic Steatohepatitis NASH and Compensated Liver Cirrhosis
Status:
COMPLETED
Status Verified Date:
2022-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
FALCON 2
Brief Summary:
This is a study of experimental medication BMS-986036 given to adults with Nonalcoholic Steatohepatitis NASH the buildup of fat and inflammation in the liver that is not caused by alcohol and liver cirrhosis liver damage characterized by normal liver tissue being replaced by scar tissue
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None